Bladder Cancer — SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
Citation(s)
Phase II Study on SCH 66336 (Farnesyl Protein Transferase Inhibitor) and Gemcitabine as Second Line Treatment in Advanced Metastatic Urothelial Cancer - EORTC Study 16997